Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

26.68 -0.67 (-2.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
NASDAQ:APLS Long Term Investor Notice: Investigation of Potential Wrongdoing at Apellis Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 11/14/2023 -- Certain directors of Apellis Pharmaceuticals, Inc. are under investigation on behalf of current long-term investors in shares of Apellis Pharmaceuticals, Inc.... 
Via SBWire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why Is Apellis Pharmaceuticals Stock Trading Lower Today?
Shares of Apellis Pharmaceuticals Inc (NASDAQ: APLS) declined following a  
Via Benzinga
21 Analysts Have This to Say About Apellis Pharmaceuticals
 
Via Benzinga
Analyst Ratings for Apellis Pharmaceuticals
 
Via Benzinga
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why Apellis Pharmaceuticals Stock Popped Today
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares are trading higher Thursday after the company reported preliminary U.S. 
Via Benzinga
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue? 
Via Investor's Business Daily
The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Stocks Mixed Amid Earnings, Consumer Sentiment Data
Stocks are mixed this afternoon, as investors unpack earnings reports from several bank giants as well as economic data. 
Via Talk Markets
JPMorgan, Wells Fargo, Citigroup And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly higher, with the Dow Jones gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Why Pioneer Natural Resources Shares Are Bouncing By Around 12%; Here Are 20 Stocks Moving Premarket
Gainers Vaccinex, Inc. (NASDAQ: VCNX) shares rose 40.2% to $1.15 in pre-market trading as two large insider buys were reported after the close on Thursday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
 
Via Benzinga
Constellation Brands To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Friday
HSBC raised the price target for Constellation Brands, Inc. (NYSE: STZ) from $280 to $290. HSBC analyst Carlos Laboy maintained a Buy rating. Constellation shares fell 3.2% to close at $241.33 on... 
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
WHY: NEW YORK, NY - (NewMediaWire) - October 2, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
APLS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
NASDAQ:APLS Shareholder Alert: Deadline on October 2, 2023 Coming Up in Lawsuit Against Apellis Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 10/02/2023 -- A deadline is coming up on October 2, 2023 in the lawsuit filed for certain investors of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). 
Via SBWire
Topics Lawsuit
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
APLS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors in Excess of $100K to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLS
WHY: NEW YORK, NY - (NewMediaWire) - September 29, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between... 
Via TheNewswire.com
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.